We have investigated the role of sequence motifs in the immunoglobulin heavy chain (IgH) enhancer on its activity in myeloma and fibroblasts celllines. In transient transfection assays the transcription stimulatory activity of the enhancer is decreased in myeloma cells by mutating the E motifs 1, 2 and 3, the core motifs Cl, C2, C3 and the octamer motif (0C) and in fibroblasts by mutating E2, E3, and C2. Our results suggest that transcription factors binding to El, Cl, C3 and 0C contribute in a positive manner to the tissue specificity of the IgH enhancer.
INTRODUCTION
Enhancers are promoter elements that can activate transcription over large distances, although less efficiently than over short distances. They stimulate transcription in cis and in an orientation-independent manner from both homologous and heterologous promoter elements. Specific trans-acting factors interact with defined sequence motifs in enhancers. An important goal is to understand how the combined activity of these trans-acting factors results in the modulation of enhancer activity during differentiation and in response to various signals in the cell (for reviews see 1-3).
One of the best characterized cellular enhancers is the immunoglobulin heavy chain (IgH) enhancer, which is preferentially active in lymphoid cells (4, 5) . However a central fragment of the IgH enhancer can efficiently activate transcription in non-lymphoid cells (6-8). The IgH enhancer has been proposed to contain eight motifs (see Fig.l ) : El-4 ("Ephrussi" sequences related to 5'-CAGGTGGC-3' (9,10)), Cl-3 ("core" sequences related to 5' -G T G G^J J G -3 ' (4,5)) and OC ("octanucleotide" sequences related to S'-ATTTGCAT-S 1 , (11,12)). Studies using various cell-extracts have identified proteins which interact with some of these motifs ( Fig. 1 and 13-27 ). However from in-vitro studies it is not clear whether these proteins are transcription factors, and if they are important for determine the speci-ficity of the IgH enhancer. One approach to this problem is to determining the effects of point mutating their binding sites on the activity of the enhancer in vivo. We report here the effect of mutating the eight proposed IgH enhancer motifs on its ability to activate transcription in both myeloma and fibroblast cell-lines.
MATERIALS AND METHODS
All recombinants were constructed by standard techniques (28). The wild type and mutated enhancer fragments A,B,C and D (Fig.l) were assembled from synthetic oligonucleotides by the shot-gun ligation technique (29) . The wild type and mutant fragments were sequenced to assure that the only differences between them were the intended mutations. These fragments were transferred into the reporter recombinants pG4 and pGl (see Fig. 1 ) using appropriate unique restriction sites which were introduced on the ends of the fragments during synthesis. Naturally occuring restriction sites were used to assemble the ABC fragment (see Fig. 1 ). The reporter recombinants were transfected into MPC11BU4 and LMTK" fibroblasts, and 48h later total RNA was extracted and analysed by quantitative SI nuclease mapping (6,30,31). Suitably exposed autoradiograms were analyzed by scanning densitometry. The average standard deviation was ± 10%, and the largest standard deviation observed was ± 15% (see error bars on Figs). Point mutations were created in the different motifs of the ABC DNA fragment (see Fig. 1 and Materials and Methods), and their effects on enhancer activity in myeloma cells was determined. Mutation of the OC, Cl, C3, El and E2 motifs reproducibly decreased enhancer activity (Fig. 3) . Mutating the OC motif has the largest effect suggesting that this motif is particularly important for IgH enhancer activity in myeloma cells.
HintI

E3 and C2 are also functional motifs in myeloma cells
Mutations in E3, C2 and E4 had only small inhibitory effects, which were not very significant due to the experimental errors (see error bars which give the value of one standard deviation). The effects of mutating the latter motifs might not be very large because the other motifs compensate for loss of enhancer activity. Consequently, we subdivided the enhancer into (Fig. 4, bars labelled M ) . In contrast fragment A was inactive (Fig. 4) , despite the presence of the El motif which is functional in the context of the ABC enhancer fragment (see Fig. 3 ). Mutations in the B fragment of the E3 and C2 motifs, as well as the E2, Cl and C3 motifs, decreased its transcription stimulatory activity (Fig. 5) . The latter motifs (E2, Cl and C3) had already been shown to be functional in the context of the ABC enhancer fragment (Fig.3) . Mutation in the C fragment of the OC motif abolished the stimulatory activity of the fragment, whereas mutation of the E4 motif had no effect (Fig. 5) . These results show that the E3 and C2 motifs can function in myeloma cells, even though their mutation does not lead to a large decrease in the activity of the ABC enhancer fragment. In contrast, mutation of E4 apparently had no effect using either type of reporter recombinant (Figs. 3, 5 ) . However, we cannot exclude that the mutation of the motif could have had an effect in another context. This is strikingly demonstrated by the behaviour of the El motif. This motif was functional in the ABC fragment of the pG4 reporter, but not in the A fragment in the pGl reporter (Fig. 4 and results not shown) . The D fragment contains the El-3 motifs, and activates transcription in myeloma cells (Fig. 4 ) .
Mutating the El motif did not decrease the activity of this fragment, whereas mutating E2 and E3 decreased its activity (results not shown). This suggests that the El motif may only be active when motifs other than E2 and E3 are present (see Discussion). The E3, E2 and C2 motifs are functional in fibroblasts We and others have shown that a central fragment of the IgH enhancer can stimulate transcription in non-lymphoid cells, such as mouse fibroblasts (6-8).
In agreement with these results we found that fragment B in pGl-B stimulated transcription from the fl globin promoter in LMTK' fibroblasts, whereas fragments A, C and D were inactive (Fig. 4 ) . Mutations in the E3, C2 and E2 motifs decreased the transcription stimulatory activity of the B fragments, whilst mutations in Cl and C3 had no effect (Fig. 5 ) . These results show that the E3, E2, C2 IgH enhancer motifs are functional in fibroblasts, whereas the OC, Cl, C3 and El motifs are only functional in myeloma cells. It is surprising that the D fragment is inactive in fibroblasts despite the presence of two functional motifs.
DISCUSSION
We have shown that mutating the El-3, Cl-3 and OC motifs of the IgH enhancer decreases its ability to stimulate transcription in myeloma cells, whereas mutating the E4 motif has no effect. The results for the E and OC motifs agree with those of several recent reports. Lenardo (Fig. IB, 9, 10) . Conversely, specific enhancer binding proteins have been described whose activity has not been studied in vivo in transfection assays (eg. see ref. 13 and LN4, LC2 Fig.l and ref. 18 and IgPE-2, Fig. 1 ). In addition, factors have been detected which bind to sequences adjacent to the ABC fragment (24) and we found that sequences outside this fragment and in the larger Xbal fragment contribute to enhancer activity, suggesting that these proteins may be transcription factors. Non-B cell extracts contain factors binding to El, E2, E3 and OC (13, 16, 17, 19-22, 24, 25) but factors binding to C2 have not been reported although this motif is active in vivo. Clearly further work is required to establish why the El and OC factors, which are present in these extracts, apparently do not functionally interact with the IgH enhancer in vivo, and to search for a factor which binds to the C2 motif.
The combined activity of multiple factors accounts for the overall activity of enhancers (see reviews 1-3). The emerging mechanism which accounts for the specificity of the IgH enhancer in vivo is that both cellspecific and ubiquitous positively acting transcription factors interact with and account for the activity of the enhancer in B cells. The inactivity of the enhancer in non-B cells results both from the absence of some of positive transcription factors which can functionally interact with the enhancer, and from the presence of negative elements which influence its cell-type specificity (6-7,31,40) .
